 Onconova Therapeutics, Inc. ONTX, a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes MDS today announced an investigator-initiated Phase 12a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated KRAS lung adenocarcinoma has begun enrolling patients. Over half of non-small cell lung cancers are classified as lung adenocarcinomas; of these, the largest subset has a KRAS mutation as the predominant genetic driver, said Dr. Steven Fruchtman, President and CEO, Onconova Therapeutics. The investigator-initiated trial is an open-label, dose-escalating Phase 1 study followed by a Phase 2a dose-expansion phase to study the combination of oral rigosertib and nivolumab in metastatic KRAS lung adenocarcinoma patients who have progressed on standard frontline treatment. 